Provided by Tiger Trade Technology Pte. Ltd.

Aldeyra Therapeutics

4.96
-0.0500-1.00%
Post-market: 4.96-0.0023-0.05%19:08 EST
Volume:822.77K
Turnover:4.10M
Market Cap:298.41M
PE:-6.88
High:5.12
Open:5.02
Low:4.93
Close:5.01
52wk High:7.20
52wk Low:1.14
Shares:60.16M
Float Shares:48.48M
Volume Ratio:0.25
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.9389
ROE:-64.31%
ROA:-28.94%
PB:6.06
PE(LYR):-5.28

Loading ...

Promising Developments and Strategic Partnerships Drive Buy Rating for Aldeyra Therapeutics

TIPRANKS
·
Oct 09

Aldeyra price target raised to $7 from $6 at Jefferies

TIPRANKS
·
Oct 09

High Growth Tech Stocks In The US Market With Promising Potential

Simply Wall St.
·
Sep 29

Alkermes plc Appoints Joshua Reed as New Chief Financial Officer

Reuters
·
Sep 12

Aldeyra Therapeutics Receives Orphan Designation from European Medicines Agency for ADX-2191 to Treat Rare Vitreoretinal Lymphoma

Reuters
·
Aug 28

Aldeyra Therapeutics Inc - No Approved Treatment for Primary Vitreoretinal Lymphoma in EU

THOMSON REUTERS
·
Aug 28

Aldeyra Therapeutics Receives Orphan Designation From the European Medicines Agency for Adx-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, Including Primary Vitreoretinal Lymphoma

THOMSON REUTERS
·
Aug 28

Aldeyra Therapeutics Receives FDA Fast Track Designation for ADX-2191 in Treating Retinitis Pigmentosa

Reuters
·
Aug 19

Aldeyra Therapeutics Inc - Phase 2/3 Trial of Adx-2191 Expected to Start in 2025

THOMSON REUTERS
·
Aug 19

Aldeyra Therapeutics Receives Fast Track Designation for Adx‑2191 for the Treatment of Retinitis Pigmentosa

THOMSON REUTERS
·
Aug 19

Michael Alfieri, Principal Financial Officer, Reports Acquisition of Common Shares of Aldeyra Therapeutics Inc

Reuters
·
Aug 16

Stephen Machatha, Chief Development Officer, Reports Disposal of Aldeyra Therapeutics Inc. Common Shares

Reuters
·
Aug 14

Aldeyra Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Reuters
·
Aug 09

Aldeyra Therapeutics Unveils Innovative Therapies for Immune-Mediated and Metabolic Diseases in Latest Presentation

Reuters
·
Aug 05

Aldeyra Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
Jul 29

Aldeyra Therapeutics Secures Orphan Designation from European Medicines Agency for ADX-2191 to Treat Retinitis Pigmentosa

Reuters
·
Jul 24

Aldeyra Therapeutics Inc - Phase 2/3 Trial of Adx-2191 Expected in 2025

THOMSON REUTERS
·
Jul 24

Aldeyra Therapeutics Receives Orphan Designation From the European Medicines Agency for Adx-2191 for the Treatment of Inherited Retinal Dystrophies Including Retinitis Pigmentosa

THOMSON REUTERS
·
Jul 24

Aldeyra Therapeutics Announces FDA Acceptance of Reproxalap NDA for Dry Eye Disease with PDUFA Target Date Set for December 2025

Reuters
·
Jul 17

BRIEF-Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191

Reuters
·
Jun 26